怡和嘉業(301367.SZ):擬變更公司名稱、證券簡稱及修訂《公司章程》
格隆匯4月17日丨怡和嘉業(301367.SZ)公佈,為適應公司企業規模、人才數量、業務範圍不斷擴展的新態勢,公司持續推進以適應市場需求為目的的組織架構優化升級,為更加準確地體現公司未來的發展定位,公司擬變更中文名稱、證券簡稱,公司英文名稱及證券代碼保持不變。中文名稱擬變更為北京瑞邁特醫療科技股份有限公司,證券簡稱擬變更為瑞邁特。公司擬對《北京怡和嘉業醫療科技股份有限公司章程》中對應的公司基本信息作出變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.